These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 18035418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S, Wang F, He X, He Y, Li D, Sun S.
    Vaccine; 2007 Jun 15; 25(25):4853-60. PubMed ID: 17418455
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumor secreting high levels of IL-15 induces specific immunity to low immunogenic colon adenocarcinoma via CD8+ T cells.
    Araki A, Hazama S, Yoshimura K, Yoshino S, Iizuka N, Oka M.
    Int J Mol Med; 2004 Oct 15; 14(4):571-6. PubMed ID: 15375583
    [Abstract] [Full Text] [Related]

  • 11. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R, Reisfeld RA.
    Cancer Res; 2005 Apr 15; 65(8):3419-27. PubMed ID: 15833877
    [Abstract] [Full Text] [Related]

  • 12. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N.
    Clin Cancer Res; 2005 Feb 15; 11(4):1474-82. PubMed ID: 15746049
    [Abstract] [Full Text] [Related]

  • 13. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.
    Cancer Res; 2009 Feb 01; 69(3):1046-54. PubMed ID: 19176376
    [Abstract] [Full Text] [Related]

  • 14. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine.
    Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T.
    Int J Mol Med; 2006 Jun 01; 17(6):1045-52. PubMed ID: 16685414
    [Abstract] [Full Text] [Related]

  • 15. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
    Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R.
    Eur J Immunol; 2008 Apr 01; 38(4):1033-42. PubMed ID: 18350546
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.